Literature DB >> 18719151

Somatostatin analogues reduce liver volume in polycystic liver disease.

L van Keimpema, R A de Man, J P H Drenth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18719151     DOI： 10.1136/gut.2008.155721

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  21 in total

1.  Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

Authors:  Marie C Hogan; Tetyana V Masyuk; Linda Page; David R Holmes; Xujian Li; Eric J Bergstralh; Maria V Irazabal; Bohyun Kim; Bernard F King; James F Glockner; Nicholas F Larusso; Vicente E Torres
Journal:  Nephrol Dial Transplant       Date:  2012-07-06       Impact factor: 5.992

Review 2.  Rationale for early treatment of polycystic kidney disease.

Authors:  Jared J Grantham
Journal:  Pediatr Nephrol       Date:  2014-07-15       Impact factor: 3.714

3.  Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease.

Authors:  Ramón Peces; Emilio Cuesta-López; Carlos Peces; Virginia Pérez-Dueñas; Cristina Vega-Cabrera; Rafael Selgas
Journal:  Int Urol Nephrol       Date:  2010-05-07       Impact factor: 2.370

4.  Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.

Authors:  Tom J G Gevers; Frederik Nevens; Vicente E Torres; Marie C Hogan; Joost P H Drenth
Journal:  Liver Int       Date:  2015-11-09       Impact factor: 5.828

5.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Authors:  Marie C Hogan; Tetyana V Masyuk; Linda J Page; Vickie J Kubly; Eric J Bergstralh; Xujian Li; Bohyun Kim; Bernard F King; James Glockner; David R Holmes; Sandro Rossetti; Peter C Harris; Nicholas F LaRusso; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 10.121

6.  Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.

Authors:  Carlo Spirli; Valeria Mariotti; Ambra Villani; Luca Fabris; Romina Fiorotto; Mario Strazzabosco
Journal:  J Hepatol       Date:  2016-11-05       Impact factor: 25.083

7.  Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.

Authors:  Anna Caroli; Luca Antiga; Mariateresa Cafaro; Giorgio Fasolini; Andrea Remuzzi; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

8.  Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.

Authors:  Tatyana V Masyuk; Brynn N Radtke; Angela J Stroope; Jesús M Banales; Anatoliy I Masyuk; Sergio A Gradilone; Gabriella Bedekovicsne Gajdos; Natasha Chandok; Jason L Bakeberg; Christopher J Ward; Erik L Ritman; Hiroaki Kiyokawa; Nicholas F LaRusso
Journal:  Gastroenterology       Date:  2011-12-07       Impact factor: 22.682

9.  Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease.

Authors:  Paolo Onori; Romina Mancinelli; Antonio Franchitto; Guido Carpino; Anastasia Renzi; Stefania Brozzetti; Julie Venter; Heather Francis; Shannon Glaser; Douglas M Jefferson; Gianfranco Alpini; Eugenio Gaudio
Journal:  Liver Int       Date:  2013-04-25       Impact factor: 5.828

10.  Polycystic Liver Disease: The Benefits of Targeting cAMP.

Authors:  Nicholas F Larusso; Tatyana V Masyuk; Marie C Hogan
Journal:  Clin Gastroenterol Hepatol       Date:  2016-03-10       Impact factor: 11.382
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.